A Phase 1 interventional study of Ulonivirine and Methadone in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to determine the effect of ulonivirine (MK-8507) on methadone in the body. Participants will take methadone alone and then methadone with ulonivirine to see if ulonivirine changes how the body processes methadone.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main Inclusion Criteria include but are not limited to:
Exclusion Criteria
The main Exclusion Criteria include but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a stable dose of methadone orally from Day -14 through Day 16. Methadone is co-administered with one dose of oral ulonivirine on Day 2.
Drug: Ulonivirine · Drug: Methadone
Oral Tablet
Also known as: MK-8507
Oral (per local guidelines)
Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of R-Methadone
The AUC0-24 of R-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: Up to 24 hours post-dose
Dose-Normalized AUC0-24 of S-Methadone
The AUC0-24 of S-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: Up to 24 hours post-dose
Dose-Normalized Maximum Plasma Concentration (Cmax) of R-Methadone
The Cmax of R-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: Up to 24 hours post-dose
Dose-Normalized Plasma Concentration 24 Hours Postdose (C24) of R-Methadone
The C24 of R-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: 24 hours post-dose
Time to Maximum Plasma Concentration (Tmax) of R-Methadone
The Tmax of R-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: Up to 24 hours post-dose
Dose-Normalized Cmax of S-Methadone
The Cmax of S-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: Up to 24 hours post-dose
Dose-Normalized C24 of S-Methadone
The C24 of S-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: 24 hours post-dose
Tmax of S-Methadone
The Tmax of S-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: Up to 24 hours post-dose
Dose-Normalized AUC0-24 of Total Methadone
The AUC0-24 of total methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: Up to 24 hours post-dose
Dose-Normalized Cmax of Total Methadone
The Cmax of total methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: Up to 24 hours post-dose
Dose-Normalized C24 of Total Methadone
The C24 of total methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: 24 hours post-dose
Tmax of Total Methadone
The Tmax of total methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).
Time frame: Up to 24 hours post-dose
Number of Participants With Adverse Events (AEs) Following Methadone + Ulonivirine Coadministration
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants experiencing an AE following coadministration of methadone and ulonivirine will be presented.
Time frame: Up to 16 Days
Number of Participants Discontinuing Study Therapy Due to AEs Following Coadministration of Methadone and Ulonivirine
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants discontinuing study therapy due to an AE following coadministration of methadone and ulonivirine will be presented.
Time frame: Up to 16 Days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Aug 2026 to primary completion in Sep 2026, 1 month.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jan 2027 → Sep 2026 and completion Jan 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ulonivirine · Methadone